- Home
- FTRE vs RLAY Comparison
FTRE vs RLAY Comparison
Compare FTRE & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTRE
- RLAY
- Stock Information
- Founded
- FTRE 1996
- RLAY 2015
- Country
- FTRE United States
- RLAY United States
- Employees
- FTRE N/A
- RLAY N/A
- Industry
- FTRE Medical Specialities
- RLAY Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FTRE Health Care
- RLAY Health Care
- Exchange
- FTRE Nasdaq
- RLAY Nasdaq
- Market Cap
- FTRE 864.4M
- RLAY 803.4M
- IPO Year
- FTRE N/A
- RLAY 2020
- Fundamental
- Price
- FTRE $9.40
- RLAY $5.75
- Analyst Decision
- FTRE Hold
- RLAY Strong Buy
- Analyst Count
- FTRE 9
- RLAY 8
- Target Price
- FTRE $12.06
- RLAY $17.25
- AVG Volume (30 Days)
- FTRE 1.5M
- RLAY 1.6M
- Earning Date
- FTRE 11-07-2025
- RLAY 11-05-2025
- Dividend Yield
- FTRE N/A
- RLAY N/A
- EPS Growth
- FTRE N/A
- RLAY N/A
- EPS
- FTRE N/A
- RLAY N/A
- Revenue
- FTRE $2,733,500,000.00
- RLAY $8,355,000.00
- Revenue This Year
- FTRE N/A
- RLAY $27.33
- Revenue Next Year
- FTRE N/A
- RLAY $8.87
- P/E Ratio
- FTRE N/A
- RLAY N/A
- Revenue Growth
- FTRE N/A
- RLAY N/A
- 52 Week Low
- FTRE $3.97
- RLAY $1.78
- 52 Week High
- FTRE $25.28
- RLAY $7.07
- Technical
- Relative Strength Index (RSI)
- FTRE 53.01
- RLAY 78.08
- Support Level
- FTRE $9.25
- RLAY $5.17
- Resistance Level
- FTRE $9.89
- RLAY $5.72
- Average True Range (ATR)
- FTRE 0.57
- RLAY 0.28
- MACD
- FTRE -0.12
- RLAY 0.08
- Stochastic Oscillator
- FTRE 45.93
- RLAY 98.35
About FTRE Fortrea Holdings Inc.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).